Your session is about to expire
← Back to Search
Cholinesterase Inhibitor
Pyridostigmine Bromide 60 Milligrams (mg) for Hoarseness
Phase 4
Waitlist Available
Led By Benjamin Rubinstein, MD
Research Sponsored by Eastern Virginia Medical School
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 minutes
Awards & highlights
Summary
This trial tests if pyridostigmine can improve voice quality in patients with spasmodic dysphonia who have a breathy voice after their usual treatment. The medication helps muscles work better, which might enhance their voice.
Eligible Conditions
- Hoarseness
- Spastic Dysphonia
- Spasmodic Dysphonia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 15 minutes
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 minutes
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Adapted Borg Scale Pre- and Post-Pyridostigmine (Mestinon)
CAPE-V Pre- and Post-Pyridostigmine (Mestinon)
Glottal Function Index Pre- and Post-Pyridostigmine (Mestinon)
+1 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Pyridostigmine (Mestinon)Experimental Treatment1 Intervention
Pyridostigmine (Mestinon) will be assigned to patients in this arm.
Find a Location
Who is running the clinical trial?
Eastern Virginia Medical SchoolLead Sponsor
72 Previous Clinical Trials
15,709 Total Patients Enrolled
Benjamin Rubinstein, MDPrincipal InvestigatorEastern Virginia Medical School Department of Otolaryngology - Head and Neck Surgery
1 Previous Clinical Trials
40 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger